Research Article

The Value of Left Atrial Volume Changes in Predicting Cardiotoxicity in Patients Undergoing Anthracycline Chemotherapy

Dongliang Chen, Li Fan, Yifei Rui, and Zining Yan

Department of Echocardiography, The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, Changzhou 213003, China

Correspondence should be addressed to Zining Yan; yanzining_edu@163.com

Received 5 January 2022; Revised 10 February 2022; Accepted 15 February 2022; Published 24 March 2022

Academic Editor: Bhagyaveni M.A

Copyright © 2022 Dongliang Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In order to study the value of left atrial volume three-dimensional echocardiography in predicting cardiotoxicity in patients with multiple myeloma undergoing anthracycline chemotherapy, a total of 53 patients with multiple myeloma who are treated in the Department of Hematology of our hospital from January 2018 to December 2020 are selected as the research object, and all patients underwent three cycles (T1–T3) of chemotherapy. Before and after each cycle of chemotherapy, the patients are examined with 3D ultrasound and serology detection. These patients are divided into the cardiotoxicity group and noncardiotoxicity group. The serological indexes and three-dimensional echocardiographic parameters between two groups are compared. Multivariate logistic regression is used to determine the independent risk factors of cardiotoxicity in patients undergoing chemotherapy. And ROC curves are performed to evaluate the diagnostic value of related indicators in predicting cardiotoxicity. A total of 53 patients with multiple myeloma are included in this study. Serological indexes (T3 cTnI and T3 Pro-BNP), T2 LAVmin, T3 LAVmin, T2 LAVprep, and T3 LAVprep in the cardiotoxicity group are significantly higher than those in the noncardiotoxicity group. Multivariate logistic regression further found that T3 cTnI, T3 Pro-BNP, T2 LAVmin, T3 LAVmin, T2 LAVprep, T3 LAVprep could be used to predict the occurrence of cardiotoxicity (P < 0.05). The results of ROC curves showed that T3 LAVmin had the most diagnostic efficiency of cardiotoxicity (AUC = 0.938; sensitivity 75.72%; specificity 93.82%). Detection of changes in left atrial volume using three-dimensional ultrasound could be used as strong predictors of cardiotoxicity caused by anthracycline chemotherapy drugs in patients with multiple myeloma.

1. Introduction

Multiple myeloma (MM) is a hematological malignant disease, caused by an uncontrolled clonal proliferation of plasma cells. The major characteristics of MM are an overabundance of monoclonal paraprotein, the uncontrolled proliferation and extensive infiltration of malignant plasma cells, and the synthesis inhibition of normal polyclonal immunoglobulins, resulting in a series of clinical manifestations. Multiple myeloma could affect multiple organ systems including the hematopoietic system, bone, kidney, heart, liver, and nervous system, which seriously influences the life quality of these patients [1–4].

Cardiotoxicity is reported as the most serious side effect, which included abnormalities of the myocardium, electrophysiology, and pericardium. The majority of people who develop multiple myeloma are from 50 to 60 years old, and the ratio of male to female is about 3:2. With the population aged, the incidence of MM has increased year by year. However, it still lacks a radical cure for MM. So far, chemotherapy has become as the main method of treatment. PAD chemotherapy regimen (bortezomib, dexamethasone, liposomal doxorubicin) is the current standard of care for diagnosed MM [5–7]. Anthracycline (ANT) drugs represented by doxorubicin are now widely used in the treatment of multiple myeloma. It belongs to a family of nonspecific
2. The Proposed Method

This study is approved by the Ethics Committee of The Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University, and all patients or their families provided written informed consent before research. The study included 53 patients aged 31–78 years with 30 males. These patients with multiple myeloma are scheduled to undergo anthracycline chemotherapy between January 2018 and December 2020.

The study inclusion criteria are as follows: (1) the patients are diagnosed with multiple myeloma. (2) There is no history of other tumors diseases. (3) The patients are without thoracic deformity, respiratory disease, and other diseases significantly affecting the accuracy of ultrasound. (4) Before chemotherapy, LVEF indicator is normal in the examination of conventional echocardiography. (5) The estimated survival time is more than 2 years. The exclusion criteria are as follows: (1) the patients are with congenital heart disease, chronic coronary artery disease, myocarditis, and other diseases affecting cardiac function. (2) The patients are considered as cardiac dysfunction before chemotherapy through conventional echocardiography, electrocardiograph, and other laboratory tests. (3) Anthracycline or other drugs affecting cardiac function are used before.

2.1. Chemotherapy Regimens. PDA (bortezomib + pegylated liposomal doxorubicin + dexamethasone) regimen is performed in all the patients with diagnosed multiple myeloma. During the chemotherapy cycle, 30 mg/m² pegylated liposomal doxorubicin is intravenously injected on day 1; 1.3 mg/m² bortezomib is intravenously injected on day 1, 4, 8, 11; and 20 mg dexamethasone is intravenously injected on day 1–2, 4–5, 8–9, 11–12. The chemotherapy is repeated every 3 weeks as a course. The patients have applied 3 courses of treatment. According to the chemotherapy cycle and checkpoints, the time points for examination are as follows: before chemotherapy (T0), the first cycle of chemotherapy (T1), the second cycle of chemotherapy (T2), and the third cycle of chemotherapy (T3).

2.2. Serologic Examination. CTNI and NT-proBNP are cardiac markers detected in our study with a routine blood sample at different time points. The serum is separated from venous blood by centrifugation at the speed of 3000 rpm under the condition of 4°C. cTNI and NT-proBNP are assessed by the automatic biochemistry analyzer (Hitachi, Japan).

2.3. Echocardiography. All the patients underwent three-dimensional echocardiographic evaluation at different time points with an X5-1 probe and an application frequency of 2.0–3.5 MHz. All the evaluations are performed and analyzed with QLab software installed. The following indicators are examined: minimum left atrium volume (LAVmin), maximum left atrium volume (LAVmax), left atrium volume before contraction (LAVprep), left atrium ejection fraction (LAEF), and left ventricular ejection fraction (LVEF). One cardiologist is blinded to patients’ history, types of chemotherapy drugs administered, and biochemical markers and interpreted echocardiograms. Cardiotoxicity is defined as a fall of EF >10% from the baseline EF value during follow-up echocardiography. Definite diagnosis of cardiotoxicity is conducted during chemotherapy cycles. These patients are divided into the cardiotoxicity group and cardiotoxicity group according to the LVEF changes.

2.4. Statistical Analysis. The statistical analysis is performed using SPSS19.0 and MedCalc 22.0. Normally, distributed quantitative data are expressed as mean ± standard deviation (SD). The t-test is used to determine differences between two groups. Count data are presented as rate (%) and are analyzed using the χ² test or Fisher’s exact probability test. Multivariate logistic regression analysis is conducted to explore the relationship between the cardiac risk factors and incidence of cardiotoxicity. The odds ratios (OR) and 95% confidence intervals (CIs) are obtained from regression coefficients. In addition, ROC curves are performed, and the diagnostic efficiency of these parameters is evaluated by the
area under the ROC curve. P value ≤0.05 is considered a significantly statistical difference.

3. The Clinical Results

3.1. Comparison of Basic Information. In total, 53 cases of patients with multiple myeloma are included in this research, and their clinical and demographic characteristics are summarized in Table 1. Echocardiography is performed before the administration of anthracyclines and during the follow-up period. According to whether △LVEF >10% occurred one year after chemotherapy, these patients are divided into cardiotoxicity group (N = 10) and noncardiotoxicity group (N = 43). The incidence rate of cardiotoxicity in patients undergoing anthracycline chemotherapy is 18.87%. No significant differences in age, gender, BMI, thyroid disease, lung disease, and cardiovascular risk factors are found between two groups.

3.2. Comparison of cTNI and Pro-BNP. The levels of cTNI and Pro-BNP are compared at different points during the follow-up period between two groups, as shown in Table 2. There is an upward trend in terms of cTNI and Pro-BNP levels. The significant differences in cTNI or Pro-BNP levels are found between two groups at the T3 time point (P < 0.05).

3.3. Comparison of Echocardiographic Indicators. Table 3 shows the echocardiographic parameters of each group in different chemotherapy periods. The minimum left atrium volume (LAV_min), maximum left atrium volume (LAV_max), and left atrium volume before contraction (LAV_prep) of two groups continued to increase during follow-up. Compared with noncardiotoxicity group at T2 and T3 time points, LAV_min, LAV_max, and LAV_prep values in the cardiotoxicity group are significantly increased. And there are significant differences between two groups (P < 0.05). Figure 1 shows imaging analysis of the left atrium in patients.

3.4. Multivariate Logistic Regression Analyses. The diagnostic values of these indexes in predicting cardiotoxicity in patients with multiple myeloma undergoing anthracycline chemotherapy are performed using multivariate logistic regression analyses. As shown in Table 4, the results of multivariate logistic regression analyses revealed that T3 cTnI, T3 Pro-BNP, T2 LAV_min, T3 LAV_min, T2 LAV_prep, and T3 LAV_prep are independent risk factors for predicting cardiotoxicity in patients with multiple myeloma undergoing anthracycline chemotherapy.

3.5. ROC Curves Results. Further study is performed to analyze the diagnostic efficiency of these indexes for predicting cardiotoxicity in multiple myeloma patients undergoing anthracycline chemotherapy using ROC curves. As shown in Table 5, the results showed that the area under the curve (AUC) in ROC curves is listed from high to low: T3 LAV_min, T2 LAV_min, T3 Pro-BNP, T3 LAV_prep, T2 LAV_prep, and T3 cTnI. Figure 2 displays the results of ROC curves analyses.

4. The Clinical Analysis

Anthracycline chemotherapeutics for treating MM patients could cause a loss of heart function and, in severe cases, affect the prognosis of these patients [14]. Therefore, the heart function of MM patients should be monitored in time during chemotherapy, and the amount of chemotherapy drug should be adjusted in time to reduce the cardiotoxicity risk of anthracycline drugs according to the monitoring results [15–17]. Therefore, this research evaluated the changes of left atrium function using serum indicators and three-dimensional ultrasound during chemotherapy. The results of this study revealed that the indicators associated with the left atrium in three-dimensional ultrasound could early predict cardiotoxicity in MM patients who underwent anthracyline chemotherapy. It had good clinical application value.

Reactive oxygen species including superoxide free radicals and hydroxyl free radicals are generated in the metabolism process of anthracycline chemotherapeutic drugs. Lipid molecules on the cell membrane surface are oxidized by hydroxyl free radicals, and it is helpful to generate malondialdehyde. The produced malondialdehyde could diffuse among cells and destroy important molecular structures in cells [18, 19]. Due to the lack of antioxidant enzymes for reactive oxygen species metabolism in cardiomyocytes, the cardiotoxicity effects of anthracyline chemotherapeutics are more common [20]. Myocardial biopsy is the gold standard for the evaluation of cardiotoxicity, but it is a traumatic examination and difficult to popularize [21]. It is reported that it is difficult for two-dimensional ultrasound to detect subtle differences after cardiac injury, and conventional ultrasound indicators are not suitable for early detecting cardiotoxicity [22–24].

Serological indicators such as cTnI and Pro-BNP had certain advantages in the early prediction of myocardial injury because they are released into the blood after myocardial injury [25]. ROC curve results in this study showed that T3 cTnI and T3 Pro-BNP (AUC = 0.751, 0.852) had the potential to predict cardiotoxicity. Unfortunately, the patient had completed three chemotherapy cycles at that time. These two indicators could not be considered as markers for early guiding patients to choose the dose of chemotherapy drugs. It is needed to combine other examination methods to achieve the early prediction.

Three-dimensional echocardiography is more accurate in evaluating the volume of the left atrium in contrast to conventional echocardiography. It could dynamically display the changes of various indicators for the left atrium volume in real time without depending on the geometric shape of the left atrium. The high sensitivity of three-dimensional echocardiography is reported in predicting cardiovascular adverse events.

The physiological roles of the left atrium consisted of storage function, channeling function, and pump function, which played an important role in maintaining left
In the early period of diastole, the left ventricular filling mainly depended on the storage function and channeling function. And in the late period of diastole, initiative atrial systole depending on pump function is the key point for left ventricular filling. The mild or moderate left ventricular diastolic dysfunction usually led to increased pump function of the left atrium [26]. Reduced myocardial contraction of the left ventricular could cause excessive left ventricular end-diastolic volume, further lead to decreased left ventricular compliance and increased left ventricular filling. In the early period of diastole, the left ventricular filling mainly depended on the storage function and channeling function. And in the late period of diastole, initiative atrial systole depending on pump function is the key point for left ventricular filling. The mild or moderate left ventricular diastolic dysfunction usually led to increased pump function of the left atrium [26]. Reduced myocardial contraction of the left ventricular could cause excessive left ventricular end-diastolic volume, further lead to decreased left ventricular compliance and increased left ventricular

**Table 1:** Comparison of basic information between two groups.

| Parameters                  | Cardiotoxicity group (N = 10) | Noncardiotoxicity group (N = 43) | t/χ² value | P value |
|-----------------------------|--------------------------------|----------------------------------|------------|---------|
| Male/female (n)             | 3/7                            | 9/34                             | 0.381      | 0.537   |
| Age (years)                 | 46.84 ± 5.72                   | 47.13 ± 6.24                     | 0.134      | 0.894   |
| BMI (kg/m²)                 | 26.04 ± 3.52                   | 25.84 ± 3.47                     | 0.0164     | 0.871   |
| Thyroid disease (n/%)       | 1 (10.00%)                     | 3 (6.98%)                        | 0.1075     | 0.7444  |
| Lung disease (n/%)          | 1 (10.00%)                     | 4 (9.30%)                        | 0.005      | 0.946   |
| Cardiovascular risk factors (n/%) |                              |                                  |            |         |
| Smoking                     | 1 (10.00%)                     | 5 (11.63%)                       | 0.021      | 0.884   |
| Hypertension                | 2 (20.00%)                     | 9 (20.93%)                       | 0.004      | 0.948   |
| Hyperlipidemia              | 2 (20.00%)                     | 11 (25.58%)                      | 0.137      | 0.712   |
| Diabetes                    | 3 (30.00%)                     | 14 (32.56%)                      | 0.024      | 0.876   |

**Table 2:** Comparison of serological indicators at different time points between two groups.

| Index         | Group                  | T0        | T1        | T2        | T3        | F value | P value |
|---------------|------------------------|-----------|-----------|-----------|-----------|---------|---------|
| cTnI (ng/mL)  | Cardiotoxicity (N = 10)| 0.023 ± 0.011 | 0.025 ± 0.013 | 0.026 ± 0.019 | 0.039 ± 0.015* | 5.208   | 0.006   |
|               | Noncardiotoxicity (N = 43)| 0.020 ± 0.015 | 0.023 ± 0.018 | 0.024 ± 0.015 | 0.024 ± 0.013 |         |         |
| Pro-BNP (pg/mL)| Cardiotoxicity (N = 10)| 94.44 ± 19.39 | 95.92 ± 19.73 | 100.93 ± 21.49 | 122.38 ± 20.38* | 5.583   | 0.003   |
|               | Noncardiotoxicity (N = 43)| 81.29 ± 28.94 | 83.39 ± 31.29 | 91.92 ± 29.30 | 95.63 ± 28.39 |         |         |

Note: compared with noncardiotoxicity group, * P < 0.05.

**Table 3:** Table of echocardiographic parameters at different time points in patients with and without cardiotoxicity.

| Index          | Group                  | T0        | T1        | T2        | T3        | F value | P value |
|----------------|------------------------|-----------|-----------|-----------|-----------|---------|---------|
| LAVmin (mL)    | Cardiotoxicity (N = 10)| 16.83 ± 2.07 | 17.93 ± 2.51 | 20.62 ± 1.47* | 22.94 ± 1.91* | 5.201   | 0.007   |
|                | Noncardiotoxicity (N = 43)| 16.13 ± 3.92 | 16.63 ± 3.29 | 18.39 ± 1.84 | 19.84 ± 2.72 |         |         |
| LAVmax (mL)    | Cardiotoxicity (N = 10)| 38.82 ± 4.96 | 39.11 ± 5.23 | 40.28 ± 5.28 | 42.82 ± 6.02 | 4.713   | 0.011   |
|                | Noncardiotoxicity (N = 43)| 36.18 ± 5.29 | 38.72 ± 6.28 | 39.13 ± 5.65 | 40.89 ± 5.39 |         |         |
| LAVprep (mL)   | Cardiotoxicity (N = 10)| 25.92 ± 5.29 | 26.29 ± 4.68 | 28.83 ± 3.17* | 29.99 ± 5.53* | 2.934   | 0.049   |
|                | Noncardiotoxicity (N = 43)| 24.88 ± 4.02 | 25.18 ± 3.79 | 26.69 ± 4.03 | 26.11 ± 4.18 |         |         |
| LAEF (%)       | Cardiotoxicity (N = 10)| 54.65 ± 8.34 | 53.52 ± 7.75 | 52.42 ± 8.25 | 51.54 ± 8.27 | 1.243   | 0.295   |
|                | Noncardiotoxicity (N = 43)| 55.65 ± 9.43 | 54.54 ± 8.43 | 54.14 ± 9.65 | 53.83 ± 8.42 |         |         |

Note: compared with noncardiotoxicity group, * P < 0.05.

**Figure 1:** Imagination analysis of left atrium in patients.
LAVmin, and LAVprep are closely correlated with the left ventricular diastolic dysfunction [29]. The change of left ventricular diastolic pressure could affect the left atrium. Compared with the left ventricular, the wall of the left atrium is thinner, and it is more sensitive to the increased pressure of the left atrium, which easily leads to the increased volume of the left atrium. LAV max as the left atrium volume at the end of the left ventricular systole, is not only affected by the left ventricular diastolic function but also by the longitudinal mechanical traction of the left ventricular myocardial fibers. LAV min could directly reflect the left ventricular diastolic function without being affected by the left ventricular systolic function. This is because the left atrial pressure is basically equal to the left ventricular pressure due to the opening of the mitral valve in the left ventricle end diastole. For the evaluation of left ventricular diastolic function, LAV min is more sensitive than LAV max [32]. Similarly, this study also found that three-dimensional ultrasound indicators (LAV min and LAV prep) had more advantages in assessing the degree of left atrium injury. This study also revealed that LAV min and LAV prep gradually increased with the cycle of chemotherapy, and the differences between the groups are statistically significant, which suggested that the cardiotoxic effect of chemotherapy drugs led to reduced left ventricular diastolic function and had high sensitivity. Multivariate logistic regression analysis showed that T2 LAV min, T3 LAV prep, T2 LAV prep, and LAV prep could independently predict the occurrence of cardiotoxicity. The remarkable thing is that LAV min and LAV prep had a certain value in the diagnosis of cardiotoxicity after the second cycle of chemotherapy (AUC = 0.892, 0.762). After the third cycle of chemotherapy, the diagnostic efficacy is further improved (AUC = 0.938, 0.823), and it is higher than the traditional serological indicators such as cTnI and Pro-BNP. Therefore, the prediction of cardiotoxicity in patients based on the results of three-dimensional ultrasound had good clinical value and could be applied for evaluating the cardiotoxicity of MM patients in real time during chemotherapy.

There are some limitations in this study. First is the small sample size. Second, all the patients are recruited from one center. The third is a short duration of patients follow-up, and long-term follow-up is necessary to identify the significance of these early observations. Fourth, the time for changes in markers should be exactly identified. And more frequent blood sampling is needed. Therefore, conducting a multicenter, long-term, large-sample clinical study on cardiac toxicity to analyze the predicting values of left atrial volume changes in patients with multiple myeloma undergoing anthracycline chemotherapy is warranted for more precise detection of myocardial injury.

5. Conclusion and Prospect

The main aim of this research is to investigate the predictive value of echocardiographic parameters in the examination of anthracycline-related cardiac toxicity in multiple myeloma patients. This study has shown that the change of left atrial volume is a strong predictor of cardiotoxicity. Therefore, the
assessment of left atrial volume changes might be a useful tool in the evaluation of patients with multiple myeloma undergoing anthracycline chemotherapy at risk of developing cardiotoxicity. This will help in the monitoring of these patients after they are treated with anthracycline chemotherapy and lead to the potential reduction in mortality and morbidity in these patients.

Data Availability
All data included in this study are available upon request by contact with the corresponding author.

Conflicts of Interest
All authors declare that they have no conflicts of interest.

References
[1] B. Garibaldi and D. Zaas, "An unusual case of cardiac amyloidosis," Journal of General Internal Medicine, vol. 22, no. 7, pp. 1047–1052, 2007.
[2] A. Bhagat and E. S. Kleinerman, "Anthracycline-Induced cardiotoxicity: causes, mechanisms, and prevention," Advances in Experimental Medicine & Biology, vol. 1257, pp. 181–192, 2020.
[3] J. V. McGowan, R. Chung, A. Maulik, I. Piotrowska, J. M. Walker, and D. M. Yellon, "Anthracycline chemotherapy and cardiotoxicity," Cardiovascular Drugs and Therapy, vol. 31, no. 1, pp. 63–75, 2017.
[4] L. C. M. Kremer, H. J. H. van der Pal, M. Offringa, and M. M. MUGGIA, "Risk factors for doxorubicin-induced congestive heart failure," Annals of Internal Medicine, vol. 91, no. 5, pp. 710–717, 1979.
[5] D. Keefe, "Anthracycline-induced cardiomyopathy," Seminars in Oncology, vol. 28, no. 4, pp. 2–7, 2001.
[6] E. Sadurska, "Current views on anthracycline cardiotoxicity in Childhood cancer survivors," Pediatric Cardiology, vol. 36, no. 6, pp. 1112–1119, 2015.
[7] L. C. M. Kremer, H. J. H. van der Pal, M. Offringa, E. C. van Dalen, and P. A. Voûte, "Frequency and risk factors of subclinical cardiotoxicity after anthracyline therapy in children: a systematic review," Annals of Oncology, vol. 13, no. 6, pp. 819–829, 2002.
[8] S. E. Lipszul, T. L. Miller, R. E. Scully et al., "Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes," Journal of Clinical Oncology, vol. 30, no. 10, pp. 1042–1049, 2012.
[9] E. S. Christenson, T. James, V. Agrawal, and B. H Park, "Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity," Clinical Biochemistry, vol. 48, no. 4/5, pp. 223–235, 2015.
[10] V. N. Costa, R. M. Y. Nomura, S. Miyadahira, R. P. Vieira Francisco, and M. Zugaib, "Cord blood B-type natriuretic peptide levels in placental insufficiency: correlation with fetal Doppler and pH at birth," European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 171, no. 2, pp. 231–234, 2013.
[11] W. A. M. Esteves, L. Lodi-junqueira, C. P. F. Neto et al., "The impact of right ventricular stroke work on B-type natriuretic peptide levels in patients with mitral stenosis undergoing percutaneous mitral valvuloplasty," Journal of Interventional Cardiology, vol. 26, no. 5, pp. 501–508, 2013.
[12] Y.-D. Wang, S.-X. Chen, and L.-Q. Ren, "Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity," Oncology Letters, vol. 11, no. 5, pp. 3483–3492, 2016.
[13] P. Vejpongsa and E. T. H. Yeh, "Prevention of anthracycline-induced cardiotoxicity," Journal of the American College of Cardiology, vol. 64, no. 9, pp. 938–945, 2014.
[14] P. Hantsou, "Mechanisms of toxic cardiomyopathy," Clinical Toxicology, vol. 57, no. 1, pp. 1–9, 2019.
[15] J. Allen, J. D. Thomson, J. J. Lewis, and J. L. Gibbs, "Mitral regurgitation after anthracycline treatment for childhood malignancy," Heart, vol. 85, no. 4, pp. 430–432, 2001.
[16] P. Milberg, D. Fleischer, J. Stymmann et al., "Reduced repolarization reserve due to anthrecyline therap facilitates torsade de points induced by IKr blockers," Basic Research in Cardiology, vol. 102, no. 1, pp. 42–51, 2007.
[17] J. L. Zamorano, P. Lancelotti, and D. Rodriguez Muñoz, "ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC), European Journal of Heart Failure, vol. 19, no. 1, pp. 9–42, 2016.
[18] J. C. Plana, M. Galdersi, A. Barac et al., "Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging," European Heart Journal - Cardiovascular Imaging, vol. 15, no. 10, pp. 1063–1093, 2014.
[19] L. E. Sade, "Speckle tracking strain imaging: practical approach for application," Turk Kardiyojiyoji Dermeli Arsivi : Turk Kardiyojiyoji Dermelinin yayin organidir, vol. 45, no. 2, pp. 197–205, 2017.
[20] K. Kalam, P. Otahal, and T. H. Marwick, "Prognostic implications of global LV dysfunction: a systematic review and Meta-analysis of global longitudinal strain and ejection fraction," Heart, vol. 100, no. 21, pp. 1673–1680, 2014.
[21] H. Sawaya, I. A. Sebag, J. C. Plana et al., "Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab," Circulation: Cardiovascular Imaging, vol. 5, no. 5, pp. 596–603, 2012.
[22] M. T. Maeder, "Research Highlights: ultrasensitive cardiac troponin and myocardial strain predict cardiotoxicity," Biomarkers in Medicine, vol. 6, no. 6, pp. 785–788, 2012.
[23] H. Sawaya, I. A. Sebag, J. C. Plana et al., "Early detection and prediction of cardiotoxicity in chemotherapy-treated patients," The American Journal of Cardiology, vol. 107, no. 9, pp. 1375–1380, 2011.
[24] H. Xiao, X. Wang, S. Li, Y. Liu, Y. Cui, and X. Deng, "Advances in biomarkers for detecting early cancer treatment-related cardiac dysfunction," Frontiers in Cardiovascular Medicine, vol. 8, Article ID 753313, 2021.
[25] M. Gabani, D. Castañeda, Q. M. Nguyen et al., "Association of cardiotoxicity with doxorubicin and trastuzumab: a double-edged sword in chemotherapy," Cureus, vol. 13, no. 9, Article ID e18194, 2021.
[26] H. Miyoshi, Y. Oishi, Y. Mizuguchi et al., "Association of left atrial reservoir function with left atrial structural remodeling related to left ventricular dysfunction in asymptomatic patients with hypertension: evaluation by two-dimensional speckle-tracking echocardiography," Clinical and Experimental Hypertension, vol. 37, no. 2, pp. 155–165, 2015.
[27] A. Motoc, B. Roosens, E. Scheirlynck et al., “Feasibility and reproducibility of left atrium measurements using different three-dimensional echocardiographic modalities,” Diagnostics, vol. 10, no. 12, p. 1043, 2020.

[28] F. Zhou, L. Niu, M. Zhao, W.-X. Ni, and J. Liu, “Real-time three-dimensional echocardiography predicts cardiotoxicity induced by postoperative chemotherapy in breast cancer patients,” World Journal of Clinical Cases, vol. 8, no. 12, pp. 2542–2553, 2020.

[29] M. Yamano, T. Yamano, Y. Iwamura et al., “Impact of left ventricular diastolic property on left atrial function from simultaneous left atrial and ventricular three-dimensional echocardiographic volume measurement,” The American Journal of Cardiology, vol. 119, no. 10, pp. 1687–1693, 2017.

[30] N. I. Bouwer, C. Liesting, M. J. M. Kofflard et al., “2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab,” Cardiovasc Ultrasound, vol. 19, no. 1, p. 35, 2021.

[31] S. Hatipoglu, N. Ozdemir, M. O. Omaygenc et al., “Left atrial expansion index is an independent predictor of diastolic dysfunction in patients with preserved left ventricular systolic function: a three dimensional echocardiography study,” The International Journal of Cardiovascular Imaging, vol. 30, no. 7, pp. 1315–1323, 2014.

[32] K. Wakami, N. Ohte, K. Asada et al., “Correlation between left ventricular end-diastolic pressure and peak left atrial wall strain during left ventricular systole,” Journal of the American Society of Echocardiography, vol. 22, no. 7, pp. 847–851, 2009.